Alzheimers Market: Developer Landscape and Competitive Insights
It was estimated that, in 2018, nearly 5.7 million Americans (considering all age groups) were living with Alzheimers. During the same year, Alzheimer’s pipeline and other dementias were projected to be responsible for a healthcare burden amounting to USD 277 billion, in the US. Despite extensive research aimed at comprehending the etiopathogenesis of Alzheimers, only six drugs have been approved since 1998 for treatment. The rate of failure of drugs being developed for treating Alzheimers is alarming (~99.6%) and is even higher than that reported for cancer (~81%). At present, several stakeholders in the pharmaceutical industry are engaged in efforts to develop various types of disease modifying interventions and drug / therapy candidates that offer symptomatic relief.
I have highlighted below some of the most interesting insights from our study. You can also access additional details Alzheimer’s Disease Market.
Alzheimers, cited among the leading causes of mortality in geriatric patients, imposes a significant burden on the modern healthcare system owing to the lack of adequate tools to facilitate early diagnosis and limited treatment options.
Insights from social media and other online information portals indicate the existence of a significant unmet need for effective treatment options and methods to facilitate early diagnosis of Alzheimers.
Presently, over 200 molecules are being evaluated, including certain repositioned or repurposed drugs, for treating different stages of the disease
Several molecules are in late stages of clinical development; based on a variety of established and novel therapeutic principles, these molecules are designed for delivery via diverse routes of administration
Innovation in this domain is being by both industry and academic players, and is evident across published scientific literature; there are several drug development programs against known biological targets
Despite extensive research efforts and a burgeoning pipeline, only six drugs are commercially available; among the reported reasons for failure, inability to achieve study (primary / secondary) endpoints is the most common.
Several investors have realized the lucrative opportunity associated with drug candidates being developed to treat this clinical condition; over USD 2.8 billion has been raised across 180 instances recently
To learn more, please click Alzheimer’s Disease Market. For any queries / suggestions, please do not hesitate to contact us at sales@rootsanalysis.com. You can also download the SAMPLE REPORT on Alzheimers by Roots Analysis.
Our Social Media Platform
SARM1 Inhibitor: A Solution Against Neurodegenerative Disorders
Injected Version of Eisai/Biogen Alzheimer’s Drug Works as Well as IV Leqembi
Alzheimers Treatment and Its Evolving Market
About Author
Arun_Gupta
Arun is an enthusiastic professional and has been associated with Roots Analysis since the very early years. He has led multifaceted roles over the years be it business research, consulting, competitive intelligence, IT & technology, sales and marketing. He currently drives strategic thinking and execution within the sales and marketing domain. With educational background in life sciences from Thapar University and digital marketing credentials from Indian School of Business, he has led a lot of critical initiatives at the organization. His background in life sciences has been one of the key reasons for quick understanding and implementation of customized marketing strategies. During his early years, he has led multiple consulting assignments for global clients ranging from competitive landscaping, deal structuring and preparing go-to-market strategy for his clients.